NovaBridge Biosciences (NBP) Long-Term Deferred Tax (2017 - 2022)
NovaBridge Biosciences (NBP) reported Long-Term Deferred Tax of $2.5 million for Q4 2022, down 53.41% quarter-over-quarter from $5.4 million in Q4 2018.
NovaBridge Biosciences (NBP) Long-Term Deferred Tax (2017 - 2022) Analysis & Trends
NovaBridge Biosciences (NBP) has 3 years of Long-Term Deferred Tax data on file, last reported at $2.5 million in Q4 2022.
- Long-Term Deferred Tax for Q4 2022 came in at $2.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $2.5 million (changed N/A YoY), and the FY2022 annual result was $2.6 million, changed N/A from the prior year.
- Long-Term Deferred Tax fell to $2.5 million in Q4 2022 per NBP's latest filing, from $5.4 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $5.4 million in Q4 2018 and troughed at $2.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.51 Mn |
| Dec 31, 2018 | 5.38 Mn |
| Dec 31, 2017 | 5.62 Mn |